Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc. is positioned favorably in the biotechnology sector, with its pipeline of therapies, particularly Axpaxli, showcasing strong potential for robust and durable benefits in treating ophthalmic diseases. The company's strategy for accelerating the New Drug Application (NDA) submission timeline for Axpaxli could lead to a market entry ahead of competitors, enhancing its competitive advantage and revenue prospects. Additionally, the positive data trends and strong safety profile, as indicated by key opinion leaders, support a favorable outlook for widespread adoption of Axpaxli in clinical settings.

Bears say

Ocular Therapeutix has faced significant losses since its inception, raising concerns about its long-term financial stability and sustainability. Despite meeting primary endpoints in clinical trials, the stock price saw a notable decline of approximately 22%, indicating investor skepticism about the company’s future performance. Additionally, increased market competition from existing and emerging therapies poses risks to Ocular’s market penetration and pricing strategies, further compounding the negative outlook for the company's stock.

Ocular Therapeutix (OCUL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.